DailyIQ
Last updatedUpdating…

BDX·Becton, Dickinson and Company

$187.25
-0.12 (-0.06%)
High
$189.68
Open
$188.26
Market Cap
50.97B
52W High
$195.19
Low
$186.04
P. Close
$187.25
P/E
54.11
52W Low
$129.65
Fwd P/E
14.09
DailyIQ Est.
$197.72
Inst. Ownership
40.9%
Short Interest
3.59%
Days to Cover
4.9
Div. Yield
2.12%
Next Ex-Div
~Dec 9
Div. Growth
42+ yrs
Technical Score (1D)
91
BULLISH
News Sentiment
36
BEARISH
On Oct 13, Becton Dickinson and Company reported that its revenue for the quarter rose 5.4% while earnings fell 34.3%, a decline attributed to higher costs rather than a drop in demand for its medical devices. The company noted that cash conversion remained healthy, with operating cash flow exceeding net income after capital expenditures. The earnings miss was described as a material negative impact on BDX’s financial performance. No other developments were reported for the company on that date.
LOW TARGET
$165 -11.9%
2 analysts
MEAN TARGET
$194 +3.6%
13 analysts
HIGH TARGET
$225 +20.2%
8 analysts
PRICE RANGE
$165.00 - $225.00
SB / B / H / S / SS
5/7/9/1/1
DAILYIQ EST.
$197.72 (+5.6%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NYQ
Country
United States
Website
Symbol
BDX
Description
Becton, Dickinson and Company (BDX) is a global medical technology firm focused on improving healthcare outcomes through innovative products and services. The company's core business revolves around four key segments: Medical, Connected Care, BioPharma Systems, and Interventional and Life Sciences. BDX offers a comprehensive portfolio of medical supplies, devices, and diagnostic solutions, including vascular access technologies, medication management systems, and laboratory equipment. Through strategic collaborations, like the one with ChemoGLO, BDX is committed to advancing healthcare worker safety and improving patient care. Founded in 1897, the company is headquartered in Franklin Lakes, New Jersey, and serves a diverse customer base across the healthcare spectrum.
Bought (1Y)
0 shares
$0
Sold (1Y)
15,194 shares
$2.0M
Feld MichaelEVP, Chief Revenue Officer
Sell76 shares2026-09-28
Roque VitorEVP & Chief Financial Officer
Tax Withholding190 shares2026-09-02
Feld MichaelEVP, Chief Revenue Officer
Sell165 shares2026-08-26
Feld MichaelEVP, Chief Revenue Officer
Tax Withholding1,049 shares2026-08-20
Polen Thomas E JrChairman, CEO and President
Option Exercise43,278 shares2026-08-13
68/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
45.4%
Net Margin
7.7%
Revenue CAGR
7.2%
Current Ratio
1.11x
Debt / Equity
0.76x
Return on Equity
6.6%
Earnings Summary
Becton, Dickinson and Company (BDX) is a global medical technology firm that designs and manufactures a broad range of medical supplies, devices, and diagnostic solutions, operating across Medical, Connected Care, BioPharma Systems, and Interventional and Life Sciences segments. The company’s portfolio includes vascular access technologies, medication management systems, and laboratory equipment, positioning it firmly within the Medical Instruments & Supplies sector of healthcare. In the most recent fiscal year, BDX delivered a steady revenue trajectory, with Q1 2026 revenue of $5.252 billion versus $5.272 billion in Q1 2025, a slight decline of 0.4%, while Q2 2026 revenue of $4.714 billion matched Q2 2025’s $4.714 billion, indicating flat year‑over‑year performance. EPS, however, showed a more dynamic pattern: Q1 2026 EPS of $2.91 fell short of the $3.312 forecast, whereas Q2 2026 EPS of $2.90 exceeded the $2.775 estimate, reflecting a 4.5% beat. Across the last four quarters, BDX has consistently met or surpassed earnings estimates in three of the four periods, with revenue growth remaining modest but stable. Historically, the company has maintained double‑digit revenue growth over the past five years, while EPS growth has been more variable, often aligning with or slightly exceeding analyst expectations; the most recent two quarters demonstrate a return to earnings beats after a miss in Q1 2026. Recent news highlights the successful AGILITY trial for the Revello Vascular Covered Stent, which met primary safety and effectiveness endpoints, reinforcing BD’s leadership in peripheral vascular innovation and potentially supporting future revenue streams. Additionally, a $19 billion partnership with the U.S. government to expand domestic production of critical medical consumables underscores a strategic focus on supply‑chain resilience and manufacturing expansion.

EPS

EstBeatMiss
$2.60$2.98$3.37$3.75$4.14Q2'25Q3'25Q1'26Q2'26Q3'26Q4'25
QtrEstActual+/−
Q4'25$2.81 - -
Q3'26$3.17$3.23+1.8%
Q2'26$2.77$2.90+4.5%
Q1'26$3.31$2.91-12.1%
Q3'25$3.91$3.96+1.1%
Q2'25$3.40$3.68+8.2%

Revenue

EstBeatMiss
$4.5B$4.9B$5.3B$5.7B$6.1BQ2'25Q3'25Q1'26Q2'26Q3'26Q4'25
QtrEstActual+/−
Q4'25$5.2B - -
Q3'26$4.9B$5.0B+1.0%
Q2'26$4.7B$4.7B-0.0%
Q1'26$5.5B$5.3B-5.0%
Q3'25 - $5.9B -
Q2'25 - $5.5B -

Market Data

BDX Stock Snapshot

BULLISH91/100
$187.25−$0.12 (0.1%)
Market cap
50.97B
P/E ratio
54.1
Day range
$186.04 – $189.68
News sentiment
36/100 · Bearish
Analyst target
$194.08 (+3.6%)
Consensus
Hold · 23 analysts
52-week range+44.4% off low · -4.1% from high
$129.65$195.19
Price $187.25 DailyIQ Est. $197.72

Price is in the upper part of its 52-week range, and the momentum read backs that positioning up. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into BDX?

FAIR

At today's price, Becton, Dickinson and Company needs to grow free cash flow about 5.5% a year for the next 10 years to justify its valuation at a 6.84% cost of capital. Over its actual history it has compounded free cash flow at 7.2% a year, so the market is asking for 1.6 percentage points below its own delivered rate. On that basis BDX looks priced roughly in line with its own growth record.

Implied FCF growth
5.5%
Historical FCF CAGR
7.2%
Growth gap
-1.6 pts
Verdict
FAIR
Discount rate (WACC)
6.84%
Beta
0.62

Behaviour On Record

What BDX's own history says about today's numbers

Realized volatility (21d)
23.0% 69th pct
Below its peak
-17.4%
vs 200-day average
+14.4%
Up days (1y)
47%

Becton, Dickinson and Company is currently running 23.0% annualised volatility over the last 21 sessions. Measured against BDX's own 13 years of daily returns rather than a market-wide average, that is the 69th percentile — a little above its own norm, against a typical reading of 19.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BDX is trading -17.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.9%, and the deepest was -34.0% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +14.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 96th percentile — a wider gap than this stock usually carries. Over the past year BDX closed higher on 47% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, BDX finished the month higher 6 of 13 times, with a median return of -0.1% and an average of +0.3%. Its strongest month historically has been July at +4.0% on average, its weakest September at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BDX has opened more than 2% away from the prior close in 72 of 3,267 sessions (2.2% of the time), with the largest gaps running +35.8% and -8.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 4 dated reports on file, BDX moved an average of 1.9% in the session after earnings, closing higher 2 of those 4 times, with a median move of -0.3% and a largest of -3.6%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against BDX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BDX's sector?

Becton, Dickinson and Company sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for BDX?

CallsPuts

For Becton, Dickinson and Company's nearest expiry (2026-10-16, 2 days out), open interest is roughly balanced between puts and calls (put/call ratio of 1.04), with at-the-money implied volatility around 32.2%. The options market is pricing roughly a ±2.2% move by that expiry — a range of about $183.15–$191.47.

Put/call ratio (2026-10-16)
1.04
ATM implied volatility
32.2%
Total open interest
3,237
Expected move by 2026-10-16
±2.2% ($183.15–$191.47)

Analyst Rating Changes

Are analysts turning bullish or bearish on BDX?

Barclays most recently initiated coverage on Becton, Dickinson and Company to Underweight on Oct 7, 2026 with a price target of $165. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Barclays — Underweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysInitiatedUnderweight$165
Aug 31, 2026B of A SecuritiesMaintainedNeutral$185 → $200
Aug 13, 2026RBC CapitalMaintainedSector Perform$180 → $190
Aug 7, 2026CitigroupMaintainedBuy$198 → $204
Aug 7, 2026RBC CapitalMaintainedSector Perform$175 → $180
Aug 7, 2026Piper SandlerMaintainedNeutral$161 → $175
Aug 7, 2026Wells FargoMaintainedEqual-Weight$161 → $170
Aug 5, 2026TD CowenMaintainedHold$163 → $182
Jul 28, 2026UBSInitiatedBuy$190
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$190 → $180
May 11, 2026BarclaysMaintainedOverweight$202 → $204
May 8, 2026Wells FargoMaintainedEqual-Weight$157 → $161

Peers & ETF holders

BDX peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

36/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Becton, Dickinson and Company reported a 5.4% increase in revenue for the quarter, yet earnings fell sharply by 34.3%. The decline was attributed to higher costs rather than a drop in demand for its medical devices. Despite the earnings dip, the company’s cash conversion remained healthy, with operating cash flow exceeding net income after capital expenditures. The earnings miss signals a material negative impact on the company’s financial performance.
What did this article say?
Becton Dickinson (BDX) has consistently outperformed earnings estimates in its last two quarters, with a 3.78% average surprise. The most recent quarter saw earnings of $3.23 per share versus a consensus estimate of $3.14, a 2.87% beat. Earlier, BDX posted $2.90 against an expected $2.77, a 4.69% upside. Analysts note that rising estimates and a strong Zacks Earnings ESP support expectations of another earnings beat. The company’s solid ranking suggests continued upside potential for investors.
What did this article say?
Becton Dickinson released nine‑month AGILITY trial data showing its Revello Vascular Covered Stent met the primary endpoint in iliac artery disease. The company also announced a new U.S. government manufacturing partnership and a leadership change in its Surgery unit. A separate product recall highlighted execution risk, but the overall clinical and operational gains reinforced investor confidence. Over the past 90 days the stock rose 20.28%, reflecting the positive momentum from these developments. The combined clinical success and manufacturing expansion positioned BDX for continued growth.
What did this article say?
Becton, Dickinson and Company (BDX) announced that it will host an audio webcast on November 5, 2026 to discuss its fourth‑quarter and full‑year fiscal 2026 financial results, which ended September 30, 2026. The company will release a news release and presentation materials with summary financial information prior to the call. The webcast and related materials will be available on BD’s investor relations website. The announcement signals BD’s intent to provide transparency to investors and to outline its operational strategy for the upcoming year.
What did this article say?
Becton, Dickinson and Company announced a $19 billion partnership with the U.S. government to expand domestic manufacturing of medical consumables. The deal includes a commitment to produce all U.S. needles using American-made steel and provides relief from future Section 232 tariffs. The investment is intended to strengthen supply‑chain resilience and give BD greater control over high‑volume consumables. The partnership signals a strategic shift toward domestic production and aligns with U.S. policy priorities. The move is expected to enhance BD’s market position and reduce tariff exposure.
What did this article say?
On October 8, 2026, Becton, Dickinson and Company (BDX) announced a collaboration with the Global Surgery Foundation and the Business Council for International Understanding to promote continuous noninvasive blood pressure monitoring for maternal care. The initiative, presented at the United Nations General Assembly, aimed to accelerate the adoption of monitoring technologies that could detect life‑threatening complications earlier and improve outcomes for mothers and newborns worldwide. The partnership underscored BDX’s commitment to advancing global health solutions and aligning with the UN Sustainable Development Goal of reducing maternal mortality.
What did this article say?
Becton, Dickinson and Company (BDX) reported data from a nine‑month AGILITY trial evaluating its Revello stent. The trial assessed the device’s performance and safety profile over the initial nine months of patient follow‑up. Early results indicated favorable outcomes, though the company noted that longer‑term data are required to confirm durability and clinical benefit. The release provides preliminary evidence that may support future regulatory submissions and market adoption of the Revello stent.
What did this article say?
Evercore ISI increased its price target for Becton, Dickinson and Company (BDX) from $180 to $210, reflecting a more optimistic view of the company’s prospects. The rating remains overweight, and the new target aligns with a bullish assessment of BDX’s earnings potential. The upgrade signals confidence in BDX’s product pipeline and market positioning, potentially influencing investor sentiment.
What did this article say?
Barclays analyst Christopher Pasquale began coverage of Becton Dickinson (NYSE:BDX) on October 7, assigning an Underweight rating. The bank set a price target of $165 per share, suggesting a modest upside relative to current market levels. The rating indicates the firm believes BDX is likely to underperform peers over the medium term. The coverage launch signals a cautious stance amid competitive pressures in the medical device sector. No immediate earnings or product announcements were cited to justify the rating.
What did this article say?
Barclays announced new coverage of Becton Dickinson and Company (BDX) on October 7, assigning an underweight rating and a $165 price target. The bank noted BDX’s prior average rating of overweight and a mean price target of $193 from other analysts. The downgrade reflects concerns over the company’s recent performance and competitive pressures. The new target represents a significant reduction from the previous consensus level, signaling a shift in analyst sentiment. This development may influence investor perception and trading activity for BDX shares.

Technical Analysis

Real-time indicators across multiple timeframes

91
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $18.35B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy36,678,93913.48%$7.12B2026-01-29
BlackRock, Inc.▼ Sell24,592,1669.04%$3.72B2026-08-07
Invesco Ltd.▼ Sell8,898,4883.27%$1.35B2026-08-14
Geode Capital Management, LLC▲ Buy8,141,5862.99%$1.23B2026-08-12
Wellington Management Group LLP▼ Sell6,357,9862.34%$962.15M2026-08-14
Norges Bank▲ Buy4,169,5231.53%$630.97M2026-08-12
Morgan Stanley▼ Sell3,319,5901.22%$502.35M2026-08-13
Bank of America Corp▲ Buy3,138,7861.15%$474.99M2026-08-14
JPMorgan Chase & Co▼ Sell2,835,6921.04%$440.07M2026-08-12
Northern Trust Corp▲ Buy2,625,2200.97%$397.27M2026-08-13
Harris Associates L P▲ Buy2,350,9630.86%$355.77M2026-08-14
Goldman Sachs Group Inc▼ Sell1,758,9210.65%$266.18M2026-08-14
Wells Fargo & Company▼ Sell1,210,7750.45%$183.23M2026-08-14
Citigroup Inc▼ Sell716,5470.26%$108.44M2026-08-03
AQR Capital Management LLC▼ Sell650,1900.24%$98.07M2026-08-14
Janus Henderson Group plc▲ Buy467,3960.17%$73.48M2026-05-18
FMR LLC (Fidelity)▼ Sell459,9290.17%$69.60M2026-08-13
Prudential Financial Inc▲ Buy434,6890.16%$65.78M2026-08-12
Gotham Asset Management, LLC▲ Buy371,4250.14%$56.21M2026-08-14
AllianceBernstein L.P.▲ Buy328,6050.12%$51.67M2026-08-14
Balyasny Asset Management L.P.▲ Buy317,1070.12%$47.99M2026-08-14
Neuberger Berman Group LLC▲ Buy302,5670.11%$45.96M2026-08-13
Two Sigma Investments, LP▲ Buy293,8390.11%$44.47M2026-08-14
Squarepoint Ops LLC▲ Buy253,4850.09%$38.36M2026-08-14
Citadel Advisors LLC▼ Sell118,8430.04%$17.98M2026-09-02
Q2 2026 flow:3.48M sh bought ($526.39M)6.85M sh sold ($1.04B)net -3.37M sh (−$513.31M)
Congressional Trading Activity
14 disclosed trades · ~$185.5K est. traded value · 7 buys, 7 sells
MemberChamberStateTypeAmountTradedFiled
Thomas H. KeanHouseNJ07▼ Sell$1K - $15K2026-05-212026-06-18
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Kevin HernHouseOK01▼ Sell$15K - $50K2026-03-172026-04-03
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-242025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-172025-08-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Thomas H. KeanHouseNJ07▲ Buy$1K - $15K2025-05-132025-06-17
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-03-052025-04-11
Shelley Moore CapitoSenateWV▼ Sell$1K - $15K2024-02-152024-03-15
Tommy TubervilleSenateAL▼ Sell$15K - $50K2021-10-182021-11-10
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2018-04-242019-05-09
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2018-04-052019-05-09
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2016-04-192016-05-04